Skip to main content
    B

    Baxter International Inc (BAX)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NYSE

    $25.55
    -0.26 (-1.03%)

    Market Cap: $13.35B

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Baxter International Inc (BAX) Earnings: Report Dates and Results

    Updated Oct 29, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Baxter International (BAX) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, Baxter International reported EPS of $0.58, above the $0.51 estimate. It beat the EPS estimate in 6 of the last 8 quarters.

    Earnings

    Performance (10Y)

    Beat Rate
    78%(31/40)
    Avg Surprise
    +6.65%
    Streak
    3 Q

    Upcoming Estimates

    Reports Feb 10, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus$0.60
    Range$0.56 - $0.64
    15 analysts
    Revenue Consensus
    $3.12B
    Range$3.00B - $3.28B
    14 analysts
    Reports Apr 28, 2027 (est.)Period ending Mar 31, 2027
    EPS Consensus$0.41
    Range$0.35 - $0.51
    8 analysts
    EPS Revisions
    2
    3
    30d
    EPS Estimate DriftChange to current
    90d ago$0.45-8.6%
    60d ago$0.45-8.6%
    30d ago$0.44-6.0%
    7d ago$0.41+0.4%
    Current$0.41
    Revenue Consensus
    $2.76B
    Range$2.75B - $2.79B
    6 analysts

    Next Report

    BAX has an expected report date of Feb 10, 2027. Analysts' consensus for the quarter ending Dec 31, 2026 is 36.4% above the $0.44 reported for the quarter ended Dec 31, 2025.

    BAX Earnings Call

    The latest BAX earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 40 quarters below that had an estimate, BAX beat 31, missed 7 and matched 2. Revenue for the quarter ended Sep 30, 2026 was $2.98B, up 5.3% from $2.83B a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026$0.58$0.51$0.50 - $0.54+13.73%Beat-15.9%132 up, 7 downOct 29, 2026$2.98B
    Jun 30, 2026$0.56$0.36$0.36 - $0.38+55.56%Beat-5.1%11N/AJul 30, 2026$2.96B
    Mar 31, 2026$0.36$0.31$0.26 - $0.34+16.13%Beat-34.5%121 up, 2 downApr 30, 2026$2.70B
    Dec 31, 2025$0.44$0.54$0.52 - $0.56-18.52%Miss-24.1%141 up, 1 downFeb 12, 2026$2.97B
    Sep 30, 2025$0.69$0.60$0.58 - $0.61+15.00%Beat+40.8%131 up, 0 downOct 30, 2025$2.83B
    Jun 30, 2025$0.59$0.61$0.59 - $0.64-3.28%Miss-13.2%121 up, 0 downJul 31, 2025$2.81B
    Mar 31, 2025$0.55$0.48$0.48 - $0.49+14.58%Beat-15.4%121 up, 0 downMay 1, 2025$2.63B
    Dec 31, 2024$0.58$0.52$0.51 - $0.53+11.54%Beat-34.1%101 up, 1 downFeb 20, 2025$2.75B
    Sep 30, 2024$0.49$0.78$0.77 - $0.78-37.18%Miss-27.9%130 up, 0 downNov 8, 2024$2.70B
    Jun 30, 2024$0.68$0.66$0.60 - $0.68+3.03%Beat+23.6%140 up, 0 downAug 6, 2024$2.69B
    Mar 31, 2024$0.65$0.61$0.59 - $0.62+6.56%Beat+10.2%130 up, 0 downMay 2, 2024$2.49B
    Dec 31, 2023$0.88$0.86$0.85 - $0.88+2.33%Beat0.0%130 up, 0 downFeb 8, 2024$541.00M
    Sep 30, 2023$0.68$0.68$0.66 - $0.790.00%In line-17.1%111 up, 0 downNov 2, 2023$2.60B
    Jun 30, 2023$0.55$0.60$0.60 - $0.67-8.33%Miss-36.8%131 up, 0 downJul 27, 2023$3.71B
    Mar 31, 2023$0.59$0.49$0.47 - $0.58+20.41%Beat-36.6%130 up, 0 downApr 27, 2023$3.51B
    Dec 31, 2022$0.88$0.94$0.91 - $0.96-6.38%Miss-15.4%130 up, 1 downFeb 9, 2023N/A
    Sep 30, 2022$0.82$0.81$0.79 - $0.87+1.23%Beat-19.6%140 up, 1 downOct 27, 2022$3.61B
    Jun 30, 2022$0.87$0.87$0.85 - $0.890.00%In line+8.7%120 up, 0 downJul 28, 2022$3.59B
    Mar 31, 2022$0.93$0.81$0.75 - $0.82+14.81%Beat+22.4%130 up, 1 downApr 28, 2022$3.71B
    Dec 31, 2021$1.04$1.03$0.97 - $1.08+0.97%Beat+30.0%150 up, 0 downFeb 17, 2022$2.88B
    Sep 30, 2021$1.02$0.94$0.93 - $0.96+8.51%Beat+22.9%16N/AOct 28, 2021$3.23B
    Jun 30, 2021$0.80$0.75$0.73 - $0.81+6.67%Beat+25.0%16N/AJul 29, 2021$3.10B
    Mar 31, 2021$0.76$0.65$0.63 - $0.68+16.92%Beat-7.3%16N/AApr 29, 2021$2.95B
    Dec 31, 2020$0.80$0.76$0.73 - $0.82+5.26%Beat-17.5%16N/AFeb 4, 2021$3.18B
    Sep 30, 2020$0.83$0.72$0.69 - $0.76+15.28%Beat+12.2%16N/AOct 29, 2020$2.97B
    Jun 30, 2020$0.64$0.71$0.63 - $0.82-9.86%Miss-28.1%16N/AJul 30, 2020$2.72B
    Mar 31, 2020$0.82$0.72$0.69 - $0.75+13.89%Beat+7.9%14N/AApr 30, 2020$2.80B
    Dec 31, 2019$0.97$0.88$0.83 - $0.93+10.23%Beat+24.4%13N/AMar 17, 2020$3.04B
    Sep 30, 2019$0.74$0.84N/A-11.90%Miss-7.5%N/AN/AOct 24, 2019$2.85B
    Jun 30, 2019$0.89$0.81$0.80 - $0.83+9.88%Beat+15.6%17N/AJul 25, 2019$2.83B
    Mar 31, 2019$0.76$0.68$0.67 - $0.72+11.76%Beat+8.6%16N/AApr 25, 2019$2.64B
    Dec 31, 2018$0.78$0.73$0.71 - $0.75+6.85%Beat+21.9%17N/AJan 31, 2019$2.82B
    Sep 30, 2018$0.80$0.74$0.73 - $0.75+8.11%Beat+25.0%16N/AOct 31, 2018$2.76B
    Jun 30, 2018$0.77$0.71$0.70 - $0.73+8.45%Beat+22.2%15N/AJul 26, 2018$2.84B
    Mar 31, 2018$0.70$0.62$0.61 - $0.65+12.90%Beat+20.7%15N/AApr 26, 2018$2.68B
    Dec 31, 2017$0.64$0.59$0.57 - $0.62+8.47%Beat+12.3%14N/AFeb 1, 2018$2.80B
    Sep 30, 2017$0.64$0.59$0.56 - $0.60+8.47%Beat+14.3%16N/AOct 25, 2017$2.71B
    Jun 30, 2017$0.63$0.57$0.55 - $0.59+10.53%Beat+37.0%16N/AJul 26, 2017$2.60B
    Mar 31, 2017$0.58$0.51N/A+13.73%Beat+61.1%N/AN/AApr 26, 2017$2.48B
    Dec 31, 2016$0.57$0.52N/A+9.62%Beat+32.6%N/AN/AFeb 1, 2017$2.65B
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was $2.27, down 5.4% from the year before. It was $1.95 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025$2.27-5.4%
    Dec 31, 2024$2.40-11.1%
    Dec 31, 2023$2.70-22.9%
    Dec 31, 2022$3.50-3.3%
    Dec 31, 2021$3.62+17.2%
    Dec 31, 2020$3.09-8.0%
    Dec 31, 2019$3.36+10.2%
    Dec 31, 2018$3.05+22.5%
    Dec 31, 2017$2.49+27.7%
    Dec 31, 2016$1.95N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 7,800 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20267,83612
    2026Q2Jun 30, 20266,28414
    2026Q1Mar 31, 20268,33312
    2025Q4Dec 31, 20258,44512
    2025Q3Sep 30, 20257,81612
    2025Q2Jun 30, 20257,70811
    2025Q1Mar 31, 20257,03312
    2024Q4Dec 31, 20247,16912

    2026Q3 Earnings Call

    Opening remarks

    Kevin Moran Vice President, Investor Relations Good morning, and welcome. Today, we'll discuss Baxter's third quarter results, along with our updated financial outlook for the full year 2026. This morning, a press release was issued with our preliminary earnings results and updated outlook. The press release and investor presentation are available on the Investors section of the Baxter website. Joining me today are Andrew Hider, President and Chief Executive Officer; and John Rogers, Executive Vice President and Chief Financial Officer. During the call, we will be making forward-looking statements, including comments regarding our updated financial outlook for the full year 2026 and the anticipated drivers of the fourth quarter, the anticipated impact of various regulatory, operational and quality matters, including ones related to our infusion pump platform and ongoing supply challenges, and commentary regarding the global macroeconomic environment, including tariff impacts and the broader inflationary pressures. Forward-looking statements involve risks and uncertainties, which could cause our actual results to differ materially from our current expectations. Please refer to today's press release, the forward-looking statement slide at the beginning of our investor presentation and our SEC filings for more detail. In addition, please note, on the call, all of our comments will be on a non-GAAP basis unless they are specifically called out as GAAP. Non-GAAP financial measures are used to help investors understand Baxter's ongoing business performance. GAAP to non-GAAP reconciliations can be found in the schedules attached to our press release and our earnings presentation. On the call, we will reference organic growth, which excludes the impact of foreign exchange, MSA revenues from Vantive and impacts associated with business acquisitions or divestitures. Unless otherwise noted, all financial results on today's call reflect continuing operations and exclude Baxter's former Kidney Care business, which is reported as discontinued operations. Finally, Andrew, John and I will take questions following the prepared remarks, and we kindly ask that you limit yourself to one question and one brief follow-up so that we can give as many people in the queue an opportunity. With that, I'd like to turn the call over to Andrew.

    Andrew Hider President and Chief Executive Officer Thank you, Kevin, and good morning, everyone. Before discussing the quarter, I want to welcome John Rogers to Baxter as our new Chief Financial Officer. John joined us on October 1 and has a strong track record of leading multiple complex organizations through transformation and performance improvement. His deep financial and operational experience aligns well with our strategic priorities, and I look forward to partnering with him as we continue to advance our turnaround. Now I will turn to the quarter. Our third quarter performance provides further evidence that our turnaround is gaining traction.

    Frequently Asked Questions About BAX

    When is Baxter International's next earnings date?

    Baxter International's next earnings report is expected for Feb 10, 2027.

    Did BAX beat earnings estimates last quarter?

    Yes. Baxter International reported EPS of $0.58 for the quarter ended Sep 30, 2026, above the $0.51 estimate, a 13.73% surprise.

    What EPS do analysts expect from BAX next quarter?

    The consensus EPS estimate for Baxter International for the quarter ending Dec 31, 2026 is $0.60 from 15 analysts, with estimates from $0.56 to $0.64.

    How often does BAX beat earnings estimates?

    Baxter International beat the EPS estimate in 6 of the last 8 quarters, with an average surprise of +13.09%.